公开(公告)号：US10370422B2

公开(公告)日：2019-08-06

申请号：US15304282

申请日：2015-04-15

Applicant: The University of Liverpool

Inventor： Daniel Palmer ,  Taha Elmitwalli

IPC: C07K14/52 ,  C07K19/00 ,  C12N15/11 ,  C07K14/47 ,  C07K14/705

Abstract: Provided are compositions comprising fusion proteins, polynucleotides and/or expression vectors with therapeutic utility for suppressing and/or treating cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.

公开(公告)号：US20170044226A1

公开(公告)日：2017-02-16

申请号：US15304282

申请日：2015-04-15

Applicant: The University of Liverpool

Inventor： Daniel Palmer ,  Taha Elmitwalli

IPC: C07K14/47 ,  C07K14/705

CPC classification number: C07K14/4747 ,  C07K14/70575 ,  C07K2319/00 ,  C07K2319/03

Abstract: Provided are fusion proteins, polynucleotides and expression vectors with therapeutic utility in the prevention and/or treatment of cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.

Abstract translation: 提供了在预防和/或治疗癌症中具有治疗效用的融合蛋白，多核苷酸和表达载体，以及这些药剂的医疗用途以及使用它们的治疗方法。 本发明的融合蛋白包含提供TRAIL的细胞凋亡诱导活性的氨基酸序列和膜锚定氨基酸序列。 提供TRAIL的细胞凋亡诱导活性的氨基酸序列包含TRAIL的细胞外结构域或其片段或变体。 包含能够诱导细胞凋亡的TRAIL的氨基酸序列和将第一序列锚定在细胞膜上的第二序列的融合蛋白在减少TRAIL受体阳性细胞的活力方面比天然存在的（“野生型”）显着更有效 型“）TRAIL蛋白本身。